6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

Three	CD	three	three	three	N	O
hundred	VBD	hundred	hundred	hundr	N	O
ninety	SYM	ninety	ninety	nineti	N	O
-	:	-	-	-	N	O
five	CD	five	five	five	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
approximately	RB	approximately	approximately	approxim	N	O
250	CD	250	250	250	N	O
children	NNS	children	child	children	N	O
(	(	(	(	(	N	O
aged	VBN	aged	aged	age	N	O
2	CD	2	2	2	N	O
to	TO	to	to	to	N	O
17	CD	17	17	17	N	O
years	NNS	years	year	year	N	O
)	)	)	)	)	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
in	IN	in	in	in	N	O
interventional	JJ	interventional	interventional	intervent	N	O
trials	NNS	trials	trial	trial	N	O
in	IN	in	in	in	N	O
CAPS	NNP	caps	cap	cap	N	O
or	CC	or	or	or	N	O
SJIA	NNP	sjia	sjia	sjia	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
frequently	RB	frequently	frequently	frequent	N	O
reported	VBD	reported	reported	report	N	O
adverse	JJ	adverse	adverse	advers	N	O
drug	NN	drug	drug	drug	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
infections	NNS	infections	infection	infect	N	B-AdverseReaction
predominantly	RB	predominantly	predominantly	predominantli	N	O
of	IN	of	of	of	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
upper	JJ	upper	upper	upper	N	I-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
majority	NN	majority	majority	major	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
events	NNS	events	event	event	N	O
were	VBD	were	were	were	N	O
mild	JJ	mild	mild	mild	N	B-Severity
to	TO	to	to	to	N	I-Severity
moderate	VB	moderate	moderate	moder	N	I-Severity
although	IN	although	although	although	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
infections	NNS	infections	infection	infect	N	B-AdverseReaction
were	VBD	were	were	were	N	O
observed	VBN	observed	observed	observ	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
type	NN	type	type	type	N	O
and	CC	and	and	and	N	O
frequency	NN	frequency	frequency	frequenc	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
drug	NN	drug	drug	drug	N	O
reactions	NNS	reactions	reaction	reaction	N	O
appeared	VBD	appeared	appeared	appear	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
consistent	JJ	consistent	consistent	consist	N	O
over	IN	over	over	over	N	O
time	NN	time	time	time	N	O
.	.	.	.	.	N	O

Opportunistic	JJ	opportunistic	opportunistic	opportunist	N	B-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
have	VBP	have	have	have	N	O
also	RB	also	also	also	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
CAPS	NN	caps	cap	cap	N	O
:	:	:	:	:	N	O
The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
10%	CD	10%	10%	10%	N	O
reported	VBN	reported	reported	report	N	O
by	IN	by	by	by	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
CAPS	NNP	caps	cap	cap	N	O
treated	VBD	treated	treated	treat	N	O
with	IN	with	with	with	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
are	VBP	are	are	are	N	O
nasopharyngitis	RB	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
influenza	NN	influenza	influenza	influenza	Y	B-AdverseReaction
,	,	,	,	,	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
and	CC	and	and	and	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O

SJIA	NN	sjia	sjia	sjia	N	O
:	:	:	:	:	N	O
The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
drug	NN	drug	drug	drug	N	O
reactions	NNS	reactions	reaction	reaction	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
10%	CD	10%	10%	10%	N	O
reported	VBN	reported	reported	report	N	O
by	IN	by	by	by	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
SJIA	NNP	sjia	sjia	sjia	N	O
treated	VBD	treated	treated	treat	N	O
with	IN	with	with	with	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
are	VBP	are	are	are	N	O
infections	NNS	infections	infection	infect	N	B-AdverseReaction
(	(	(	(	(	N	O
nasopharyngitis	NN	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
and	CC	and	and	and	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	JJ	tract	tract	tract	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
and	CC	and	and	and	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O

To	TO	to	to	to	N	O
report	VB	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
Novartis	NNP	novartis	novartis	novarti	N	O
Pharmaceuticals	NNP	pharmaceuticals	pharmaceutical	pharmaceut	N	O
Corporation	NNP	corporation	corporation	corpor	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
888	CD	888	888	888	N	O
-	:	-	-	-	N	O
669	CD	669	669	669	N	O
-	:	-	-	-	N	O
6682	CD	6682	6682	6682	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	NN	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
Trial	NNP	trial	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

Treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
CAPS	NNP	caps	cap	cap	N	O

The	DT	the	the	the	N	O
data	NN	data	data	data	N	O
described	VBD	described	described	describ	N	O
herein	JJ	herein	herein	herein	N	O
reflect	JJ	reflect	reflect	reflect	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
in	IN	in	in	in	N	O
104	CD	104	104	104	N	O
adult	NN	adult	adult	adult	N	O
and	CC	and	and	and	N	O
pediatric	JJ	pediatric	pediatric	pediatr	N	O
CAPS	NNP	caps	cap	cap	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
20	CD	20	20	20	N	O
FCAS	NNP	fcas	fcas	fca	Y	O
,	,	,	,	,	N	O
72	CD	72	72	72	N	O
MWS	NNP	mws	mws	mw	N	O
,	,	,	,	,	N	O
10	CD	10	10	10	N	O
MWS	NNP	mws	mws	mw	N	O
NOMID	NNP	nomid	nomid	nomid	Y	O
(	(	(	(	(	N	O
Neonatal	NNP	neonatal	neonatal	neonat	N	O
Onset	NNP	onset	onset	onset	N	O
Multisystem	NNP	multisystem	multisystem	multisystem	N	O
Inflammatory	NNP	inflammatory	inflammatory	inflammatori	N	O
Disorder	NNP	disorder	disorder	disord	N	O
)	)	)	)	)	N	O
overlap	NN	overlap	overlap	overlap	N	O
,	,	,	,	,	N	O
1	CD	1	1	1	N	O
non	SYM	non	non	non	N	O
-	:	-	-	-	N	O
FCAS	NN	fcas	fcas	fca	Y	O
non	SYM	non	non	non	N	O
-	:	-	-	-	N	O
MWS	NN	mws	mws	mw	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
1	CD	1	1	1	N	O
misdiagnosed	VBN	misdiagnosed	misdiagnosed	misdiagnos	N	O
in	IN	in	in	in	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
(	(	(	(	(	N	O
35	CD	35	35	35	N	O
patients	NNS	patients	patient	patient	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
uncontrolled	JJ	uncontrolled	uncontrolled	uncontrol	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

Sixty	NNP	sixty	sixty	sixti	N	O
-	:	-	-	-	N	O
two	CD	two	two	two	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
exposed	VBN	exposed	exposed	expos	N	O
to	TO	to	to	to	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
for	IN	for	for	for	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
6	CD	6	6	6	N	O
months	NNS	months	month	month	N	O
,	,	,	,	,	N	O
56	CD	56	56	56	N	O
for	IN	for	for	for	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
1	CD	1	1	1	N	O
year	NN	year	year	year	N	O
and	CC	and	and	and	N	O
4	CD	4	4	4	N	O
for	IN	for	for	for	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
3	CD	3	3	3	N	O
years	NNS	years	year	year	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
total	NN	total	total	total	N	O
of	IN	of	of	of	N	O
9	CD	9	9	9	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
for	IN	for	for	for	N	O
CAPS	NNP	caps	cap	cap	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Among	IN	among	among	among	N	O
these	DT	these	these	these	N	O
were	VBD	were	were	were	N	O
vertigo	NNS	vertigo	vertigo	vertigo	Y	B-AdverseReaction
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
patients	NNS	patients	patient	patient	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
infections	NNS	infections	infection	infect	N	B-AdverseReaction
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
patients	NNS	patients	patient	patient	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
intra	JJ	intra	intra	intra	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
abdominal	JJ	abdominal	abdominal	abdomin	N	I-AdverseReaction
abscess	NN	abscess	abscess	abscess	Y	I-AdverseReaction
following	VBG	following	following	follow	N	O
appendectomy	NN	appendectomy	appendectomy	appendectomi	Y	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
patient	NN	patient	patient	patient	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
commonly	RB	commonly	commonly	commonli	N	O
reported	VBD	reported	reported	report	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
treatment	NN	treatment	treatment	treatment	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
CAPS	NNP	caps	cap	cap	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
nasopharyngitis	RB	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
influenza	NN	influenza	influenza	influenza	Y	B-AdverseReaction
,	,	,	,	,	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
.	.	.	.	.	N	O

One	CD	one	one	one	N	O
patient	NN	patient	patient	patient	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
treatment	NN	treatment	treatment	treatment	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
potential	JJ	potential	potential	potenti	N	B-Factor
infection	NN	infection	infection	infect	Y	B-AdverseReaction
.	.	.	.	.	N	O

CAPS	NNP	caps	cap	cap	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
investigated	VBD	investigated	investigated	investig	N	O
the	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
of	IN	of	of	of	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
in	IN	in	in	in	N	O
an	DT	an	an	an	N	O
8	CD	8	8	8	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
,	,	,	,	,	N	O
open	JJ	open	open	open	N	O
-	:	-	-	-	N	O
label	NN	label	label	label	N	O
period	NN	period	period	period	N	O
(	(	(	(	(	N	O
Part	NNP	part	part	part	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
followed	VBN	followed	followed	follow	N	O
by	IN	by	by	by	N	O
a	DT	a	a	a	N	O
24	CD	24	24	24	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
,	,	,	,	,	N	O
randomized	VBN	randomized	randomized	random	N	O
withdrawal	NN	withdrawal	withdrawal	withdraw	N	O
period	NN	period	period	period	N	O
(	(	(	(	(	N	O
Part	NNP	part	part	part	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
followed	VBN	followed	followed	follow	N	O
by	IN	by	by	by	N	O
a	DT	a	a	a	N	O
16	CD	16	16	16	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
,	,	,	,	,	N	O
open	JJ	open	open	open	N	O
-	:	-	-	-	N	O
label	NN	label	label	label	N	O
period	NN	period	period	period	N	O
(	(	(	(	(	N	O
Part	NNP	part	part	part	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

All	DT	all	all	all	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
150	CD	150	150	150	N	O
mg	NN	mg	mg	mg	N	O
subcutaneously	RB	subcutaneously	subcutaneously	subcutan	N	O
or	CC	or	or	or	N	O
2	CD	2	2	2	N	O
mg	NNS	mg	mg	mg	N	O
kg	VBP	kg	kg	kg	N	O
if	IN	if	if	if	N	O
body	NN	body	body	bodi	N	O
weight	NN	weight	weight	weight	Y	O
was	VBD	was	wa	wa	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
15	CD	15	15	15	N	O
kg	NNS	kg	kg	kg	N	O
and	CC	and	and	and	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
40	CD	40	40	40	N	O
kg	NNS	kg	kg	kg	N	O
(	(	(	(	(	N	O
see	VB	see	see	see	N	O
Table	NNP	table	table	tabl	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Since	IN	since	since	sinc	N	O
all	DT	all	all	all	N	O
CAPS	NNP	caps	cap	cap	N	O
patients	NNS	patients	patient	patient	N	O
received	VBD	received	received	receiv	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
in	IN	in	in	in	N	O
Part	NNP	part	part	part	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
there	EX	there	there	there	N	O
are	VBP	are	are	are	N	O
no	DT	no	no	no	N	O
controlled	VBN	controlled	controlled	control	N	O
data	NNS	data	data	data	N	O
on	IN	on	on	on	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
(	(	(	(	(	N	O
AEs	NNP	aes	aes	ae	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Data	NNS	data	data	data	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
are	VBP	are	are	are	N	O
for	IN	for	for	for	N	O
all	DT	all	all	all	N	O
AEs	NNP	aes	aes	ae	N	O
for	IN	for	for	for	N	O
all	DT	all	all	all	N	O
CAPS	NNP	caps	cap	cap	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
canakinumab	NN	canakinumab	canakinumab	canakinumab	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
CAPS	NNP	caps	cap	cap	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
no	DT	no	no	no	N	O
pattern	NN	pattern	pattern	pattern	N	O
was	VBD	was	wa	wa	N	O
observed	VBN	observed	observed	observ	N	O
for	IN	for	for	for	N	O
any	DT	any	any	ani	N	O
type	NN	type	type	type	N	O
or	CC	or	or	or	N	O
frequency	NN	frequency	frequency	frequenc	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
throughout	IN	throughout	throughout	throughout	N	O
the	DT	the	the	the	N	O
three	CD	three	three	three	N	O
study	NN	study	study	studi	N	O
periods	NNS	periods	period	period	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
Number	NNP	number	number	number	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
AEs	NNP	aes	aes	ae	N	O
by	IN	by	by	by	N	O
Preferred	NNP	preferred	preferred	prefer	N	O
Terms	NNS	terms	term	term	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
10%	CD	10%	10%	10%	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
Parts	NNP	parts	part	part	N	O
1	CD	1	1	1	N	O
to	TO	to	to	to	N	O
3	CD	3	3	3	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
Phase	NNP	phase	phase	phase	N	O
3	CD	3	3	3	N	O
Trial	NNP	trial	trial	trial	N	O
for	IN	for	for	for	N	O
CAPS	NNP	caps	cap	cap	N	O
Patients	NNS	patients	patient	patient	N	O

Preferred	JJ	preferred	preferred	prefer	N	O
Term	NNP	term	term	term	N	O
ILARISN	NNP	ilarisn	ilarisn	ilarisn	N	O
35	CD	35	35	35	N	O
n	NN	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

n	NN	n	n	n	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Events	NNS	events	event	event	N	O
35	CD	35	35	35	N	O
(	(	(	(	(	N	O
100	CD	100	100	100	N	O
)	)	)	)	)	N	O

Nasopharyngitis	RB	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
12	CD	12	12	12	N	O
(	(	(	(	(	N	O
34	CD	34	34	34	N	O
)	)	)	)	)	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
7	CD	7	7	7	N	O
(	(	(	(	(	N	O
20	CD	20	20	20	N	O
)	)	)	)	)	N	O

Influenza	NNP	influenza	influenza	influenza	Y	B-AdverseReaction
6	CD	6	6	6	N	O
(	(	(	(	(	N	O
17	CD	17	17	17	N	O
)	)	)	)	)	N	O

Rhinitis	NN	rhinitis	rhinitis	rhiniti	Y	B-AdverseReaction
6	CD	6	6	6	N	O
(	(	(	(	(	N	O
17	CD	17	17	17	N	O
)	)	)	)	)	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)	)	)	)	)	N	O

Headache	$	headache	headache	headach	Y	B-AdverseReaction
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)	)	)	)	)	N	O

Bronchitis	NN	bronchitis	bronchitis	bronchiti	Y	B-AdverseReaction
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
11	CD	11	11	11	N	O
)	)	)	)	)	N	O

Gastroenteritis	NN	gastroenteritis	gastroenteritis	gastroenter	Y	B-AdverseReaction
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
11	CD	11	11	11	N	O
)	)	)	)	)	N	O

Pharyngitis	NN	pharyngitis	pharyngitis	pharyng	Y	B-AdverseReaction
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
11	CD	11	11	11	N	O
)	)	)	)	)	N	O

Weight	NNP	weight	weight	weight	Y	B-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
11	CD	11	11	11	N	O
)	)	)	)	)	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
11	CD	11	11	11	N	O
)	)	)	)	)	N	O

Vertigo	NNP	vertigo	vertigo	vertigo	Y	B-AdverseReaction
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
11	CD	11	11	11	N	O
)	)	)	)	)	N	O

Vertigo	NN	vertigo	vertigo	vertigo	Y	O

Vertigo	NN	vertigo	vertigo	vertigo	Y	B-AdverseReaction

has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
9%	CD	9%	9%	9%	N	O
to	TO	to	to	to	N	O
14%	CD	14%	14%	14%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
CAPS	NNP	caps	cap	cap	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
exclusively	RB	exclusively	exclusively	exclus	N	O
in	IN	in	in	in	N	O
MWS	NNP	mws	mws	mw	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
reported	VBD	reported	reported	report	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
adverse	JJ	adverse	adverse	advers	N	O
event	NN	event	event	event	N	O
in	IN	in	in	in	N	O
two	CD	two	two	two	N	O
cases	NNS	cases	case	case	N	O
.	.	.	.	.	N	O

All	DT	all	all	all	N	O
events	NNS	events	event	event	N	O
resolved	VBN	resolved	resolved	resolv	N	O
with	IN	with	with	with	N	O
continued	JJ	continued	continued	continu	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
.	.	.	.	.	N	O

Injection	NNP	injection	injection	inject	Y	O
Site	NNP	site	site	site	N	O
Reactions	NNS	reactions	reaction	reaction	N	O

In	IN	in	in	in	N	O
CAPS	NNP	caps	cap	cap	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	B-AdverseReaction
injection	NN	injection	injection	inject	Y	I-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
were	VBD	were	were	were	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
9%	CD	9%	9%	9%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
Part	NNP	part	part	part	N	O
1	CD	1	1	1	N	O
with	IN	with	with	with	N	O
mild	JJ	mild	mild	mild	N	O
tolerability	NN	tolerability	tolerability	toler	N	O
reactions	NNS	reactions	reaction	reaction	N	O
;	:	;	;	;	N	O
in	IN	in	in	in	N	O
Part	NNP	part	part	part	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
one	CD	one	one	one	N	O
patient	NN	patient	patient	patient	N	O
each	DT	each	each	each	N	O
(	(	(	(	(	N	O
7%	CD	7%	7%	7%	N	O
)	)	)	)	)	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
mild	NN	mild	mild	mild	N	O
or	CC	or	or	or	N	O
a	DT	a	a	a	N	O
moderate	JJ	moderate	moderate	moder	N	O
tolerability	NN	tolerability	tolerability	toler	N	O
reaction	NN	reaction	reaction	reaction	N	O
and	CC	and	and	and	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
Part	NNP	part	part	part	N	O
3	CD	3	3	3	N	O
,	,	,	,	,	N	O
one	CD	one	one	one	N	O
patient	NN	patient	patient	patient	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
mild	JJ	mild	mild	mild	N	B-Severity
local	JJ	local	local	local	N	B-AdverseReaction
tolerability	NN	tolerability	tolerability	toler	N	I-AdverseReaction
reaction	NN	reaction	reaction	reaction	N	I-AdverseReaction
.	.	.	.	.	N	O

No	DT	no	no	no	N	B-Negation
severe	JJ	severe	severe	sever	N	B-Severity
injection	NN	injection	injection	inject	Y	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
and	CC	and	and	and	N	O
none	NN	none	none	none	N	O
led	VBD	led	led	led	N	O
to	TO	to	to	to	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
SJIA	NNP	sjia	sjia	sjia	N	O

A	DT	a	a	a	N	O
total	NN	total	total	total	N	O
of	IN	of	of	of	N	O
201	CD	201	201	201	N	O
SJIA	NNP	sjia	sjia	sjia	N	O
patients	NNS	patients	patient	patient	N	O
aged	VBD	aged	aged	age	N	O
2	CD	2	2	2	N	O
to	TO	to	to	to	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
20	CD	20	20	20	N	O
years	NNS	years	year	year	N	O
have	VBP	have	have	have	N	O
received	VBN	received	received	receiv	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
of	IN	of	of	of	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
was	VBD	was	wa	wa	N	O
investigated	VBN	investigated	investigated	investig	N	O
in	IN	in	in	in	N	O
two	CD	two	two	two	N	O
phase	NN	phase	phase	phase	N	O
3	CD	3	3	3	N	O
studies	NNS	studies	study	studi	N	O
[	VBP	[	[	[	N	O
see	VB	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14.2	CD	14.2	14.2	14.2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
SJIA	NNP	sjia	sjia	sjia	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
received	VBD	received	received	receiv	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
4	CD	4	4	4	N	O
mg	NN	mg	mg	mg	N	O
kg	NN	kg	kg	kg	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
43	CD	43	43	43	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
placebo	NN	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
41	CD	41	41	41	N	O
)	)	)	)	)	N	O
via	IN	via	via	via	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
injection	NN	injection	injection	inject	Y	O
and	CC	and	and	and	N	O
were	VBD	were	were	were	N	O
assessed	VBN	assessed	assessed	assess	N	O
at	IN	at	at	at	N	O
Day	NNP	day	day	day	N	O
15	CD	15	15	15	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
efficacy	NN	efficacy	efficacy	efficaci	N	O
endpoints	NNS	endpoints	endpoint	endpoint	N	O
and	CC	and	and	and	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
safety	NN	safety	safety	safeti	N	O
analysis	NN	analysis	analysis	analysi	N	O
up	RB	up	up	up	N	O
to	TO	to	to	to	N	O
Day	NNP	day	day	day	N	O
29	CD	29	29	29	N	O
.	.	.	.	.	N	O

SJIA	NNP	sjia	sjia	sjia	N	O
Study	NNP	study	study	studi	N	O
2	CD	2	2	2	N	O
was	VBD	was	wa	wa	N	O
a	DT	a	a	a	N	O
two	CD	two	two	two	N	O
-	:	-	-	-	N	O
part	NN	part	part	part	N	O
study	NN	study	study	studi	N	O
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
open	JJ	open	open	open	N	O
-	:	-	-	-	N	O
label	NN	label	label	label	N	O
,	,	,	,	,	N	O
single	JJ	single	single	singl	N	O
-	:	-	-	-	N	O
arm	NN	arm	arm	arm	N	O
active	JJ	active	active	activ	N	O
treatment	NN	treatment	treatment	treatment	N	O
period	NN	period	period	period	N	O
(	(	(	(	(	N	O
Part	NNP	part	part	part	N	O
I	PRP	i	i	i	N	O
)	)	)	)	)	N	O
followed	VBN	followed	followed	follow	N	O
by	IN	by	by	by	N	O
a	DT	a	a	a	N	O
randomized	JJ	randomized	randomized	random	N	O
,	,	,	,	,	N	O
double	JJ	double	double	doubl	N	O
-	:	-	-	-	N	O
blind	NN	blind	blind	blind	Y	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
,	,	,	,	,	N	O
event	NN	event	event	event	N	O
-	:	-	-	-	N	O
driven	NN	driven	driven	driven	N	O
withdrawal	NN	withdrawal	withdrawal	withdraw	N	O
design	NN	design	design	design	N	O
(	(	(	(	(	N	O
Part	NNP	part	part	part	N	O
II	NNP	ii	ii	ii	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Overall	JJ	overall	overall	overal	N	O
,	,	,	,	,	N	O
177	CD	177	177	177	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
enrolled	VBN	enrolled	enrolled	enrol	N	O
into	IN	into	into	into	N	O
the	DT	the	the	the	N	O
study	NN	study	study	studi	N	O
and	CC	and	and	and	N	O
received	VBD	received	received	receiv	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
4	CD	4	4	4	N	O
mg	NN	mg	mg	mg	N	O
kg	NN	kg	kg	kg	N	O
(	(	(	(	(	N	O
up	IN	up	up	up	N	O
to	TO	to	to	to	N	O
300	CD	300	300	300	N	O
mg	NNS	mg	mg	mg	N	O
maximum	JJ	maximum	maximum	maximum	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
Part	NNP	part	part	part	N	O
I	PRP	i	i	i	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
100	CD	100	100	100	N	O
patients	NNS	patients	patient	patient	N	O
received	VBD	received	received	receiv	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
4	CD	4	4	4	N	O
mg	NN	mg	mg	mg	N	O
kg	NN	kg	kg	kg	N	O
(	(	(	(	(	N	O
up	IN	up	up	up	N	O
to	TO	to	to	to	N	O
300	CD	300	300	300	N	O
mg	NNS	mg	mg	mg	N	O
maximum	JJ	maximum	maximum	maximum	N	O
)	)	)	)	)	N	O
every	DT	every	every	everi	N	O
4	CD	4	4	4	N	O
weeks	NNS	weeks	week	week	N	O
or	CC	or	or	or	N	O
placebo	NN	placebo	placebo	placebo	N	O
in	IN	in	in	in	N	O
Part	NNP	part	part	part	N	O
II	NNP	ii	ii	ii	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
drug	NN	drug	drug	drug	N	O
reactions	NNS	reactions	reaction	reaction	N	O
listed	VBN	listed	listed	list	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
showed	VBD	showed	showed	show	N	O
higher	JJR	higher	higher	higher	N	O
rates	NNS	rates	rate	rate	N	O
than	IN	than	than	than	N	O
placebo	NN	placebo	placebo	placebo	N	O
from	IN	from	from	from	N	O
both	DT	both	both	both	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
drug	NN	drug	drug	drug	N	O
reactions	NNS	reactions	reaction	reaction	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
treatment	NN	treatment	treatment	treatment	N	O
in	IN	in	in	in	N	O
SJIA	NNP	sjia	sjia	sjia	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
infections	NNS	infections	infection	infect	N	B-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
.	.	.	.	.	N	O

Serious	JJ	serious	serious	seriou	N	B-Severity
infections	NNS	infections	infection	infect	N	B-AdverseReaction
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
varicella	NN	varicella	varicella	varicella	Y	B-AdverseReaction
,	,	,	,	,	N	O
gastroenteritis	NN	gastroenteritis	gastroenteritis	gastroenter	Y	B-AdverseReaction
,	,	,	,	,	N	O
measles	NNS	measles	measles	measl	Y	B-AdverseReaction
,	,	,	,	,	N	O
sepsis	NN	sepsis	sepsis	sepsi	Y	B-AdverseReaction
,	,	,	,	,	N	O
otitis	NN	otitis	otitis	otiti	Y	B-AdverseReaction
media	NNS	media	medium	media	N	I-AdverseReaction
,	,	,	,	,	N	O
sinusitis	NN	sinusitis	sinusitis	sinus	Y	B-AdverseReaction
,	,	,	,	,	N	O
adenovirus	NN	adenovirus	adenovirus	adenoviru	N	B-AdverseReaction
,	,	,	,	,	N	O
lymph	JJ	lymph	lymph	lymph	N	B-AdverseReaction
node	NN	node	node	node	N	I-AdverseReaction
abscess	NN	abscess	abscess	abscess	Y	I-AdverseReaction
,	,	,	,	,	N	O
pharyngitis	NN	pharyngitis	pharyngitis	pharyng	Y	B-AdverseReaction
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
approximately	RB	approximately	approximately	approxim	N	O
4%	CD	4%	4%	4%	N	O
to	TO	to	to	to	N	O
5%	CD	5%	5%	5%	N	O
(	(	(	(	(	N	O
0.02	CD	0.02	0.02	0.02	N	O
to	TO	to	to	to	N	O
0.17	CD	0.17	0.17	0.17	N	O
per	IN	per	per	per	N	O
100	CD	100	100	100	N	O
patient	JJ	patient	patient	patient	N	O
-	:	-	-	-	N	O
days	NNS	days	day	day	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
in	IN	in	in	in	N	O
both	DT	both	both	both	N	O
studies	NNS	studies	study	studi	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
listed	VBN	listed	listed	list	N	O
according	VBG	according	according	accord	N	O
to	TO	to	to	to	N	O
MedDRA	NNP	meddra	meddra	meddra	N	O
version	NN	version	version	version	N	O
15.0	CD	15.0	15.0	15.0	N	O
system	NN	system	system	system	N	O
organ	JJ	organ	organ	organ	N	O
class	NN	class	class	class	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
Tabulated	NNP	tabulated	tabulated	tabul	N	O
Summary	NNP	summary	summary	summari	N	O
of	IN	of	of	of	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Drug	NNP	drug	drug	drug	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
from	IN	from	from	from	N	O
Pivotal	NNP	pivotal	pivotal	pivot	N	O
SJIA	NNP	sjia	sjia	sjia	N	O
Clinical	NNP	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O

n	JJ	n	n	n	N	O
number	NN	number	number	number	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
IR	NNP	ir	ir	ir	N	O
Exposure	NNP	exposure	exposure	exposur	N	O
adjusted	VBD	adjusted	adjusted	adjust	N	O
incidence	NN	incidence	incidence	incid	N	O
rate	NN	rate	rate	rate	N	O
per	IN	per	per	per	N	O
100	CD	100	100	100	N	O
patient	JJ	patient	patient	patient	N	O
-	:	-	-	-	N	O
days	NNS	days	day	day	N	O
No	DT	no	no	no	N	O
injection	NN	injection	injection	inject	Y	O
site	NN	site	site	site	N	O
reaction	NN	reaction	reaction	reaction	N	O
led	VBD	led	led	led	N	O
to	TO	to	to	to	N	O
study	VB	study	study	studi	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O

SJIA	NN	sjia	sjia	sjia	N	O

Study	NNP	study	study	studi	N	O
2	CD	2	2	2	N	O
SJIA	NNP	sjia	sjia	sjia	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O

Part	NN	part	part	part	N	O
I	PRP	i	i	i	N	O
Part	VBP	part	part	part	N	O
II	NNP	ii	ii	ii	N	O

ILARISN	NNP	ilarisn	ilarisn	ilarisn	N	O
177	CD	177	177	177	N	O
n	NN	n	n	n	N	O
(	(	(	(	(	N	O
)(	NNP	)(	)(	)(	N	O
IR	NNP	ir	ir	ir	N	O
)	)	)	)	)	N	O
ILARISN	NNP	ilarisn	ilarisn	ilarisn	N	O
50	CD	50	50	50	N	O
n	NN	n	n	n	N	O
(	(	(	(	(	N	O
)(	NNP	)(	)(	)(	N	O
IR	NNP	ir	ir	ir	N	O
)	)	)	)	)	N	O
PlaceboN	NNP	placebon	placebon	placebon	N	O
50	CD	50	50	50	N	O
n	NN	n	n	n	N	O
(	(	(	(	(	N	O
)(	NNP	)(	)(	)(	N	O
IR	NNP	ir	ir	ir	N	O
)	)	)	)	)	N	O
ILARISN	NNP	ilarisn	ilarisn	ilarisn	N	O
43	CD	43	43	43	N	O
n	NN	n	n	n	N	O
(	(	(	(	(	N	O
)(	NNP	)(	)(	)(	N	O
IR	NNP	ir	ir	ir	N	O
)	)	)	)	)	N	O
PlaceboN	NNP	placebon	placebon	placebon	N	O
41	CD	41	41	41	N	O
n	NN	n	n	n	N	O
(	(	(	(	(	N	O
)(	NNP	)(	)(	)(	N	O
IR	NNP	ir	ir	ir	N	O
)	)	)	)	)	N	O

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
infestations	NNS	infestations	infestation	infest	N	O

All	DT	all	all	all	N	O
Infections	NNP	infections	infection	infect	N	B-AdverseReaction
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
nasopharyngitis	NN	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
,	,	,	,	,	N	O
(	(	(	(	(	N	O
viral	JJ	viral	viral	viral	N	B-AdverseReaction
)	)	)	)	)	N	O
upper	JJ	upper	upper	upper	N	I-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
rhinitis	NN	rhinitis	rhinitis	rhiniti	Y	B-AdverseReaction
,	,	,	,	,	N	O
pharyngitis	NN	pharyngitis	pharyngitis	pharyng	Y	B-AdverseReaction
,	,	,	,	,	N	O
tonsillitis	NN	tonsillitis	tonsillitis	tonsil	Y	B-AdverseReaction
,	,	,	,	,	N	O
sinusitis	NN	sinusitis	sinusitis	sinus	Y	B-AdverseReaction
,	,	,	,	,	N	O
urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
gastroenteritis	NN	gastroenteritis	gastroenteritis	gastroenter	Y	B-AdverseReaction
,	,	,	,	,	N	O
viral	JJ	viral	viral	viral	N	B-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
)	)	)	)	)	N	O
97	CD	97	97	97	N	O
(	(	(	(	(	N	O
54.8%	CD	54.8%	54.8%	54.8%	N	O
)(	RB	)(	)(	)(	N	O
0.91	CD	0.91	0.91	0.91	N	O
)	)	)	)	)	N	O
27	CD	27	27	27	N	O
(	(	(	(	(	N	O
54%	CD	54%	54%	54%	N	O
)(	RB	)(	)(	)(	N	O
0.59	CD	0.59	0.59	0.59	N	O
)	)	)	)	)	N	O
19	CD	19	19	19	N	O
(	(	(	(	(	N	O
38%	CD	38%	38%	38%	N	O
)(	RB	)(	)(	)(	N	O
0.63	CD	0.63	0.63	0.63	N	O
)	)	)	)	)	N	O
13	CD	13	13	13	N	O
(	(	(	(	(	N	O
30.2%	CD	30.2%	30.2%	30.2%	N	O
)(	RB	)(	)(	)(	N	O
1.26	CD	1.26	1.26	1.26	N	O
)	)	)	)	)	N	O
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
12.2%	CD	12.2%	12.2%	12.2%	N	O
)(	RB	)(	)(	)(	N	O
1.37	CD	1.37	1.37	1.37	N	O
)	)	)	)	)	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
disorders	NNS	disorders	disorder	disord	N	O

Abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
(	(	(	(	(	N	O
upper	JJ	upper	upper	upper	N	I-AdverseReaction
)	)	)	)	)	N	O
25	CD	25	25	25	N	O
(	(	(	(	(	N	O
14.1%	CD	14.1%	14.1%	14.1%	N	O
)(	RB	)(	)(	)(	N	O
0.16	CD	0.16	0.16	0.16	N	O
)	)	)	)	)	N	O
8	CD	8	8	8	N	O
(	(	(	(	(	N	O
16%	CD	16%	16%	16%	N	O
)(	RB	)(	)(	)(	N	O
0.15	CD	0.15	0.15	0.15	N	O
)	)	)	)	)	N	O
6	CD	6	6	6	N	O
(	(	(	(	(	N	O
12%	CD	12%	12%	12%	N	O
)(	RB	)(	)(	)(	N	O
0.08	CD	0.08	0.08	0.08	N	O
)	)	)	)	)	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
7%	CD	7%	7%	7%	N	O
)(	RB	)(	)(	)(	N	O
0.25	CD	0.25	0.25	0.25	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
2.4%	CD	2.4%	2.4%	2.4%	N	O
)(	RB	)(	)(	)(	N	O
0.23	CD	0.23	0.23	0.23	N	O
)	)	)	)	)	N	O

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O

Injection	NNP	injection	injection	inject	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
reaction	NN	reaction	reaction	reaction	N	I-AdverseReaction

mild	JJ	mild	mild	mild	N	O
19	CD	19	19	19	N	O
(	(	(	(	(	N	O
10.7%	CD	10.7%	10.7%	10.7%	N	O
)	)	)	)	)	N	O
6	CD	6	6	6	N	O
(	(	(	(	(	N	O
12.0%	CD	12.0%	12.0%	12.0%	N	O
)	)	)	)	)	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
4.0%	CD	4.0%	4.0%	4.0%	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
7.3%	CD	7.3%	7.3%	7.3%	N	O
)	)	)	)	)	N	O

moderate	JJ	moderate	moderate	moder	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
1.1%	CD	1.1%	1.1%	1.1%	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
2.0%	CD	2.0%	2.0%	2.0%	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O
0	CD	0	0	0	N	O

6.2	CD	6.2	6.2	6.2	N	O
Hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O

During	IN	during	during	dure	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
no	DT	no	no	no	N	B-Negation
anaphylactic	JJ	anaphylactic	anaphylactic	anaphylact	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
CAPS	NNP	caps	cap	cap	N	O
trials	NNS	trials	trial	trial	N	O
one	CD	one	one	one	N	O
patient	NN	patient	patient	patient	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
SJIA	NNP	sjia	sjia	sjia	N	O
trials	NNS	trials	trial	trial	N	O
no	DT	no	no	no	N	O
patients	NNS	patients	patient	patient	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
.	.	.	.	.	N	O

ILARIS	NNP	ilaris	ilaris	ilari	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
administered	VBN	administered	administered	administ	N	O
to	TO	to	to	to	N	O
any	DT	any	any	ani	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
known	JJ	known	known	known	N	O
clinical	JJ	clinical	clinical	clinic	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
to	TO	to	to	to	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Contraindications	NNP	contraindications	contraindication	contraind	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

6.3	CD	6.3	6.3	6.3	N	O
Immunogenicity	NN	immunogenicity	immunogenicity	immunogen	N	O

A	DT	a	a	a	N	O
biosensor	NN	biosensor	biosensor	biosensor	N	O
binding	VBG	binding	binding	bind	N	O
assay	NN	assay	assay	assay	N	O
or	CC	or	or	or	N	O
a	DT	a	a	a	N	O
bridging	JJ	bridging	bridging	bridg	N	O
immunoassay	NN	immunoassay	immunoassay	immunoassay	N	O
was	VBD	was	wa	wa	N	O
used	VBN	used	used	use	N	O
to	TO	to	to	to	N	O
detect	VB	detect	detect	detect	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
directed	VBN	directed	directed	direct	N	O
against	IN	against	against	against	N	O
canakinumab	NN	canakinumab	canakinumab	canakinumab	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
.	.	.	.	.	N	O

Antibodies	NNS	antibodies	antibody	antibodi	N	O
against	IN	against	against	against	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
were	VBD	were	were	were	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
approximately	RB	approximately	approximately	approxim	N	O
1.5%	CD	1.5%	1.5%	1.5%	N	O
and	CC	and	and	and	N	O
3.1%	CD	3.1%	3.1%	3.1%	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
for	IN	for	for	for	N	O
CAPS	NNP	caps	cap	cap	N	O
and	CC	and	and	and	N	O
SJIA	NNP	sjia	sjia	sjia	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

No	DT	no	no	no	N	O
neutralizing	JJ	neutralizing	neutralizing	neutral	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
were	VBD	were	were	were	N	O
detected	VBN	detected	detected	detect	N	O
.	.	.	.	.	N	O

No	DT	no	no	no	N	O
apparent	JJ	apparent	apparent	appar	N	O
correlation	NN	correlation	correlation	correl	N	O
of	IN	of	of	of	N	O
antibody	NN	antibody	antibody	antibodi	N	O
development	NN	development	development	develop	N	O
to	TO	to	to	to	N	O
clinical	JJ	clinical	clinical	clinic	N	O
response	NN	response	response	respons	N	O
or	CC	or	or	or	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
was	VBD	was	wa	wa	N	O
observed	VBN	observed	observed	observ	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
CAPS	NNP	caps	cap	cap	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
employed	VBD	employed	employed	employ	N	O
the	DT	the	the	the	N	O
biosensor	NN	biosensor	biosensor	biosensor	N	O
binding	VBG	binding	binding	bind	N	O
assay	NN	assay	assay	assay	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
most	JJS	most	most	most	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
SJIA	NNP	sjia	sjia	sjia	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
employed	VBD	employed	employed	employ	N	O
the	DT	the	the	the	N	O
bridging	NN	bridging	bridging	bridg	N	O
assay	NN	assay	assay	assay	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
data	NN	data	data	data	N	O
obtained	VBN	obtained	obtained	obtain	N	O
in	IN	in	in	in	N	O
an	DT	an	an	an	N	O
assay	NN	assay	assay	assay	N	O
are	VBP	are	are	are	N	O
highly	RB	highly	highly	highli	N	O
dependent	JJ	dependent	dependent	depend	N	O
on	IN	on	on	on	N	O
several	JJ	several	several	sever	N	O
factors	NNS	factors	factor	factor	N	O
including	VBG	including	including	includ	N	O
assay	JJ	assay	assay	assay	N	O
sensitivity	NN	sensitivity	sensitivity	sensit	N	O
and	CC	and	and	and	N	O
specificity	NN	specificity	specificity	specif	N	O
,	,	,	,	,	N	O
assay	VBP	assay	assay	assay	N	O
methodology	NN	methodology	methodology	methodolog	N	O
,	,	,	,	,	N	O
sample	NN	sample	sample	sampl	N	O
handling	NN	handling	handling	handl	N	O
,	,	,	,	,	N	O
timing	NN	timing	timing	time	N	O
of	IN	of	of	of	N	O
sample	JJ	sample	sample	sampl	N	O
collection	NN	collection	collection	collect	N	O
,	,	,	,	,	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
medications	NNS	medications	medication	medic	N	O
,	,	,	,	,	N	O
underlying	VBG	underlying	underlying	underli	N	O
disease	NN	disease	disease	diseas	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
number	NN	number	number	number	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
tested	VBN	tested	tested	test	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
these	DT	these	these	these	N	O
reasons	NNS	reasons	reason	reason	N	O
,	,	,	,	,	N	O
comparison	NN	comparison	comparison	comparison	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
canakinumab	VB	canakinumab	canakinumab	canakinumab	N	O
between	IN	between	between	between	N	O
the	DT	the	the	the	N	O
CAPS	NNP	caps	cap	cap	N	O
and	CC	and	and	and	N	O
SJIA	NNP	sjia	sjia	sjia	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
or	CC	or	or	or	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
antibodies	NNS	antibodies	antibody	antibodi	N	O
to	TO	to	to	to	N	O
other	JJ	other	other	other	N	O
products	NNS	products	product	product	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
misleading	VBG	misleading	misleading	mislead	N	O
.	.	.	.	.	N	O

6.4	CD	6.4	6.4	6.4	N	O
Laboratory	NNP	laboratory	laboratory	laboratori	N	O
Findings	NNS	findings	finding	find	N	O

Hematology	NN	hematology	hematology	hematolog	N	O

During	IN	during	during	dure	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
with	IN	with	with	with	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
,	,	,	,	,	N	O
mean	JJ	mean	mean	mean	N	O
values	NNS	values	value	valu	N	O
decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
for	IN	for	for	for	N	O
white	JJ	white	white	white	N	I-AdverseReaction
blood	NN	blood	blood	blood	N	I-AdverseReaction
cells	NNS	cells	cell	cell	N	I-AdverseReaction
,	,	,	,	,	N	O
neutrophils	NNS	neutrophils	neutrophil	neutrophil	Y	I-AdverseReaction
and	CC	and	and	and	N	O
platelets	NNS	platelets	platelet	platelet	N	I-AdverseReaction
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
randomized	NN	randomized	randomized	random	N	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
portion	NN	portion	portion	portion	N	O
of	IN	of	of	of	N	O
SJIA	NNP	sjia	sjia	sjia	N	O
Study	NNP	study	study	studi	N	O
2	CD	2	2	2	N	O
decreased	VBD	decreased	decreased	decreas	N	B-AdverseReaction
white	JJ	white	white	white	N	I-AdverseReaction
blood	NN	blood	blood	blood	N	I-AdverseReaction
cell	NN	cell	cell	cell	N	I-AdverseReaction
counts	NNS	counts	count	count	N	I-AdverseReaction
(	(	(	(	(	N	O
WBC	NNP	wbc	wbc	wbc	Y	I-AdverseReaction
)	)	)	)	)	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
0.8	CD	0.8	0.8	0.8	N	B-Severity
times	NNS	times	time	time	N	I-Severity
lower	JJR	lower	lower	lower	N	I-Severity
limit	NN	limit	limit	limit	N	I-Severity
of	IN	of	of	of	N	I-Severity
normal	JJ	normal	normal	normal	N	I-Severity
(	(	(	(	(	N	O
LLN	NNP	lln	lln	lln	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
5	CD	5	5	5	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
10.4%	CD	10.4%	10.4%	10.4%	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
group	NN	group	group	group	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
4.0%	CD	4.0%	4.0%	4.0%	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
group	NN	group	group	group	N	O
.	.	.	.	.	N	O

Transient	NN	transient	transient	transient	N	B-Severity
decreases	NNS	decreases	decrease	decreas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
absolute	JJ	absolute	absolute	absolut	N	I-AdverseReaction
neutrophil	NN	neutrophil	neutrophil	neutrophil	N	I-AdverseReaction
count	NN	count	count	count	N	I-AdverseReaction
(	(	(	(	(	N	O
ANC	NNP	anc	anc	anc	N	I-AdverseReaction
)	)	)	)	)	N	O
to	TO	to	to	to	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
1	CD	1	1	1	N	B-Severity
x10	JJ	x10	x10	x10	N	I-Severity
9	CD	9	9	9	N	I-Severity
L	NNP	l	l	l	N	I-Severity
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
3	CD	3	3	3	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
6.0%	CD	6.0%	6.0%	6.0%	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
group	NN	group	group	group	N	O
compared	VBN	compared	compared	compar	N	O
to1	JJ	to1	to1	to1	N	O
patient	NN	patient	patient	patient	N	O
(	(	(	(	(	N	O
2.0%	CD	2.0%	2.0%	2.0%	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
group	NN	group	group	group	N	O
.	.	.	.	.	N	O

One	CD	one	one	one	N	O
case	NN	case	case	case	N	O
of	IN	of	of	of	N	O
ANC	NNP	anc	anc	anc	N	B-AdverseReaction
less	JJR	less	le	less	N	I-AdverseReaction
than	IN	than	than	than	N	I-AdverseReaction
0.5	CD	0.5	0.5	0.5	N	I-AdverseReaction
x10	JJ	x10	x10	x10	N	I-AdverseReaction
9	CD	9	9	9	N	I-AdverseReaction
L	NNP	l	l	l	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
group	NN	group	group	group	N	O
and	CC	and	and	and	N	O
none	NN	none	none	none	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
group	NN	group	group	group	N	O
.	.	.	.	.	N	O

Mild	NNP	mild	mild	mild	N	B-Severity
(	(	(	(	(	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
LLN	NNP	lln	lln	lln	N	B-Severity
and	CC	and	and	and	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
75	CD	75	75	75	N	B-Severity
x10	JJ	x10	x10	x10	N	I-Severity
9	CD	9	9	9	N	I-Severity
L	NNP	l	l	l	N	I-Severity
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
transient	JJ	transient	transient	transient	N	B-Severity
decreases	NNS	decreases	decrease	decreas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
platelet	NN	platelet	platelet	platelet	N	I-AdverseReaction
counts	NNS	counts	count	count	N	I-AdverseReaction
were	VBD	were	were	were	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
6.3%	CD	6.3%	6.3%	6.3%	N	O
)	)	)	)	)	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
versus	IN	versus	versus	versu	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
2.0%	CD	2.0%	2.0%	2.0%	N	O
)	)	)	)	)	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patient	NN	patient	patient	patient	N	O
.	.	.	.	.	N	O

Hepatic	JJ	hepatic	hepatic	hepat	N	O
Transaminases	NNS	transaminases	transaminase	transaminas	Y	O

Elevations	NNS	elevations	elevation	elev	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
transaminases	NNS	transaminases	transaminase	transaminas	Y	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
randomized	NN	randomized	randomized	random	N	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
portion	NN	portion	portion	portion	N	O
of	IN	of	of	of	N	O
SJIA	NNP	sjia	sjia	sjia	N	O
Study	NNP	study	study	studi	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
high	JJ	high	high	high	N	B-AdverseReaction
ALT	NNP	alt	alt	alt	N	I-AdverseReaction
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
AST	NNP	ast	ast	ast	N	I-AdverseReaction
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
3	CD	3	3	3	N	B-Severity
times	NNS	times	time	time	N	I-Severity
upper	JJ	upper	upper	upper	N	I-Severity
limit	NN	limit	limit	limit	N	I-Severity
of	IN	of	of	of	N	I-Severity
normal	JJ	normal	normal	normal	N	I-Severity
(	(	(	(	(	N	O
ULN	NNP	uln	uln	uln	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
4.1%	CD	4.1%	4.1%	4.1%	N	O
)	)	)	)	)	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
2.0%	CD	2.0%	2.0%	2.0%	N	O
)	)	)	)	)	N	O
placebo	NN	placebo	placebo	placebo	N	O
patient	NN	patient	patient	patient	N	O
.	.	.	.	.	N	O

All	DT	all	all	all	N	O
patients	NNS	patients	patient	patient	N	O
had	VBD	had	had	had	N	O
normal	JJ	normal	normal	normal	N	O
values	NNS	values	value	valu	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
next	JJ	next	next	next	N	O
visit	NN	visit	visit	visit	N	O
.	.	.	.	.	N	O

Bilirubin	NN	bilirubin	bilirubin	bilirubin	Y	O

Asymptomatic	JJ	asymptomatic	asymptomatic	asymptomat	N	O
and	CC	and	and	and	N	O
mild	JJ	mild	mild	mild	N	B-Severity
elevations	NNS	elevations	elevation	elev	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
serum	NN	serum	serum	serum	N	I-AdverseReaction
bilirubin	NNS	bilirubin	bilirubin	bilirubin	Y	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
without	IN	without	without	without	N	B-Negation
concomitant	JJ	concomitant	concomitant	concomit	N	O
elevations	NNS	elevations	elevation	elev	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
transaminases	NNS	transaminases	transaminase	transaminas	Y	I-AdverseReaction
.	.	.	.	.	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Interleukin	NNP	interleukin	interleukin	interleukin	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
blockade	NN	blockade	blockade	blockad	N	O
may	MD	may	may	may	N	O
interfere	VB	interfere	interfere	interfer	N	O
with	IN	with	with	with	N	O
immune	JJ	immune	immune	immun	N	O
response	NN	response	response	respons	N	O
to	TO	to	to	to	N	O
infections	NNS	infections	infection	infect	N	O
.	.	.	.	.	N	O

Treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
medications	NNS	medications	medication	medic	N	B-DrugClass
that	WDT	that	that	that	N	I-DrugClass
work	VBP	work	work	work	N	I-DrugClass
through	IN	through	through	through	N	I-DrugClass
inhibition	NN	inhibition	inhibition	inhibit	N	I-DrugClass
of	IN	of	of	of	N	I-DrugClass
IL	NNP	il	il	il	N	I-DrugClass
-	:	-	-	-	N	I-DrugClass
1	CD	1	1	1	N	I-DrugClass
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
infections	NNS	infections	infection	infect	N	B-AdverseReaction
.	.	.	.	.	N	O

ILARIS	NNP	ilaris	ilaris	ilari	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
increased	JJ	increased	increased	increas	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
infections	NNS	infections	infection	infect	N	B-AdverseReaction
.	.	.	.	.	N	O

Physicians	NNS	physicians	physician	physician	N	O
should	MD	should	should	should	N	O
exercise	VB	exercise	exercise	exercis	N	O
caution	NN	caution	caution	caution	N	O
when	WRB	when	when	when	N	O
administering	VBG	administering	administering	administ	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
to	TO	to	to	to	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
infections	NNS	infections	infection	infect	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
recurring	VBG	recurring	recurring	recur	N	O
infections	NNS	infections	infection	infect	N	O
or	CC	or	or	or	N	O
underlying	VBG	underlying	underlying	underli	N	O
conditions	NNS	conditions	condition	condit	N	O
which	WDT	which	which	which	N	O
may	MD	may	may	may	N	O
predispose	VB	predispose	predispose	predispos	N	O
them	PRP	them	them	them	N	O
to	TO	to	to	to	N	O
infections	NNS	infections	infection	infect	N	O
.	.	.	.	.	N	O

Discontinue	NNP	discontinue	discontinue	discontinu	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
if	IN	if	if	if	N	O
a	DT	a	a	a	N	O
patient	NN	patient	patient	patient	N	O
develops	VBZ	develops	develops	develop	N	O
a	DT	a	a	a	N	O
serious	JJ	serious	serious	seriou	N	O
infection	NN	infection	infection	infect	Y	O
.	.	.	.	.	N	O

Do	NNP	do	do	do	N	O
not	RB	not	not	not	N	O
administer	VB	administer	administer	administ	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
to	TO	to	to	to	N	O
patients	NNS	patients	patient	patient	N	O
during	IN	during	during	dure	N	O
an	DT	an	an	an	N	O
active	JJ	active	active	activ	N	O
infection	NN	infection	infection	infect	Y	O
requiring	VBG	requiring	requiring	requir	N	O
medical	JJ	medical	medical	medic	N	O
intervention	NN	intervention	intervention	intervent	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O

Live	JJ	live	live	live	N	O
vaccines	NNS	vaccines	vaccine	vaccin	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
given	VBN	given	given	given	N	O
concurrently	RB	concurrently	concurrently	concurr	N	O
with	IN	with	with	with	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
.	.	.	.	.	N	O

Prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
therapy	NN	therapy	therapy	therapi	N	O
with	IN	with	with	with	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
receive	VB	receive	receive	receiv	N	O
all	DT	all	all	all	N	O
recommended	JJ	recommended	recommended	recommend	N	O
vaccinations	NNS	vaccinations	vaccination	vaccin	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Serious	JJ	serious	serious	seriou	N	O

Infections	NNS	infections	infection	infect	N	O

ILARIS	NNP	ilaris	ilaris	ilari	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
infections	NNS	infections	infection	infect	N	B-AdverseReaction
.	.	.	.	.	N	O

Physicians	NNS	physicians	physician	physician	N	O
should	MD	should	should	should	N	O
exercise	VB	exercise	exercise	exercis	N	O
caution	NN	caution	caution	caution	N	O
when	WRB	when	when	when	N	O
administering	VBG	administering	administering	administ	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
to	TO	to	to	to	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
infections	NNS	infections	infection	infect	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
recurring	VBG	recurring	recurring	recur	N	O
infections	NNS	infections	infection	infect	N	O
or	CC	or	or	or	N	O
underlying	VBG	underlying	underlying	underli	N	O
conditions	NNS	conditions	condition	condit	N	O
which	WDT	which	which	which	N	O
may	MD	may	may	may	N	O
predispose	VB	predispose	predispose	predispos	N	O
them	PRP	them	them	them	N	O
to	TO	to	to	to	N	O
infections	NNS	infections	infection	infect	N	O
.	.	.	.	.	N	O

ILARIS	NNP	ilaris	ilaris	ilari	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
administered	VBN	administered	administered	administ	N	O
to	TO	to	to	to	N	O
patients	NNS	patients	patient	patient	N	O
during	IN	during	during	dure	N	O
an	DT	an	an	an	N	O
active	JJ	active	active	activ	N	O
infection	NN	infection	infection	infect	Y	O
requiring	VBG	requiring	requiring	requir	N	O
medical	JJ	medical	medical	medic	N	O
intervention	NN	intervention	intervention	intervent	N	O
.	.	.	.	.	N	O

Administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
if	IN	if	if	if	N	O
a	DT	a	a	a	N	O
patient	NN	patient	patient	patient	N	O
develops	VBZ	develops	develops	develop	N	O
a	DT	a	a	a	N	O
serious	JJ	serious	serious	seriou	N	O
infection	NN	infection	infection	infect	Y	O
.	.	.	.	.	N	O

Infections	NNS	infections	infection	infect	N	B-AdverseReaction
,	,	,	,	,	N	O
predominantly	RB	predominantly	predominantly	predominantli	N	O
of	IN	of	of	of	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
upper	JJ	upper	upper	upper	N	I-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
some	DT	some	some	some	N	O
instances	NNS	instances	instance	instanc	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
.	.	.	.	.	N	O

Generally	RB	generally	generally	gener	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
observed	JJ	observed	observed	observ	N	O
infections	NNS	infections	infection	infect	N	B-AdverseReaction
responded	VBD	responded	responded	respond	N	O
to	TO	to	to	to	N	O
standard	JJ	standard	standard	standard	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

Isolated	JJ	isolated	isolated	isol	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
unusual	JJ	unusual	unusual	unusu	N	B-AdverseReaction
or	CC	or	or	or	N	O
opportunistic	JJ	opportunistic	opportunistic	opportunist	N	B-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
aspergillosis	NN	aspergillosis	aspergillosis	aspergillosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
atypical	JJ	atypical	atypical	atyp	N	B-AdverseReaction
mycobacterial	JJ	mycobacterial	mycobacterial	mycobacteri	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
,	,	,	,	,	N	O
cytomegalovirus	NN	cytomegalovirus	cytomegalovirus	cytomegaloviru	N	I-AdverseReaction
,	,	,	,	,	N	O
herpes	NNS	herpes	herpes	herp	N	B-AdverseReaction
zoster	NN	zoster	zoster	zoster	N	I-AdverseReaction
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
during	IN	during	during	dure	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
causal	NN	causal	causal	causal	N	O
relationship	NN	relationship	relationship	relationship	N	O
of	IN	of	of	of	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
to	TO	to	to	to	N	O
these	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
cannot	VBP	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
excluded	VBN	excluded	excluded	exclud	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
administered	VBN	administered	administered	administ	N	O
concomitantly	RB	concomitantly	concomitantly	concomitantli	N	O
with	IN	with	with	with	N	O
tumor	NN	tumor	tumor	tumor	N	O
necrosis	NN	necrosis	necrosis	necrosi	Y	O
factor	NN	factor	factor	factor	N	O
(	(	(	(	(	N	O
TNF	NNP	tnf	tnf	tnf	N	O
)	)	)	)	)	N	O
inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	O
.	.	.	.	.	N	O

An	DT	an	an	an	N	O
increased	JJ	increased	increased	increas	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
infections	NNS	infections	infection	infect	N	B-AdverseReaction
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
IL	NNP	il	il	il	N	B-DrugClass
-	:	-	-	-	N	I-DrugClass
1	CD	1	1	1	N	I-DrugClass
blocker	NN	blocker	blocker	blocker	N	I-DrugClass
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
TNF	NNP	tnf	tnf	tnf	N	O
inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	O
.	.	.	.	.	N	O

Coadministration	NN	coadministration	coadministration	coadministr	N	O
of	IN	of	of	of	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
with	IN	with	with	with	N	O
TNF	NNP	tnf	tnf	tnf	N	O
inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
recommended	VBN	recommended	recommended	recommend	N	O
because	IN	because	because	becaus	N	O
this	DT	this	this	thi	N	O
may	MD	may	may	may	N	O
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
serious	JJ	serious	serious	seriou	N	O
infections	NNS	infections	infection	infect	N	O
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Drug	JJ	drug	drug	drug	N	O
Interactions	NNP	interactions	interaction	interact	N	O
(	(	(	(	(	N	O
7.1	CD	7.1	7.1	7.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Drugs	NNS	drugs	drug	drug	N	O
that	WDT	that	that	that	N	O
affect	VBP	affect	affect	affect	N	O
the	DT	the	the	the	N	O
immune	NN	immune	immune	immun	N	O
system	NN	system	system	system	N	O
by	IN	by	by	by	N	O
blocking	VBG	blocking	blocking	block	N	O
TNF	NNP	tnf	tnf	tnf	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
new	JJ	new	new	new	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
and	CC	and	and	and	N	O
reactivation	NN	reactivation	reactivation	reactiv	N	O
of	IN	of	of	of	N	O
latent	JJ	latent	latent	latent	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
(	(	(	(	(	N	O
TB	NNP	tb	tb	tb	Y	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

It	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
possible	JJ	possible	possible	possibl	N	O
that	IN	that	that	that	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
IL	NNP	il	il	il	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
increases	VBZ	increases	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
reactivation	NN	reactivation	reactivation	reactiv	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	I-AdverseReaction
or	CC	or	or	or	N	O
of	IN	of	of	of	N	O
opportunistic	JJ	opportunistic	opportunistic	opportunist	N	B-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
.	.	.	.	.	N	O

Prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
initiating	VBG	initiating	initiating	initi	N	O
immunomodulatory	JJ	immunomodulatory	immunomodulatory	immunomodulatori	N	O
therapies	NNS	therapies	therapy	therapi	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
for	IN	for	for	for	N	O
active	JJ	active	active	activ	N	O
and	CC	and	and	and	N	O
latent	JJ	latent	latent	latent	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
infection	NN	infection	infection	infect	Y	O
.	.	.	.	.	N	O

Appropriate	JJ	appropriate	appropriate	appropri	N	O
screening	NN	screening	screening	screen	N	O
tests	NNS	tests	test	test	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
performed	VBN	performed	performed	perform	N	O
in	IN	in	in	in	N	O
all	DT	all	all	all	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

ILARIS	NNP	ilaris	ilaris	ilari	N	O
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
studied	VBN	studied	studied	studi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
positive	JJ	positive	positive	posit	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
screen	NN	screen	screen	screen	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
of	IN	of	of	of	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
in	IN	in	in	in	N	O
individuals	NNS	individuals	individual	individu	N	O
with	IN	with	with	with	N	O
latent	JJ	latent	latent	latent	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
infection	NN	infection	infection	infect	Y	O
is	VBZ	is	is	is	N	O
unknown	JJ	unknown	unknown	unknown	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
testing	VBG	testing	testing	test	N	O
positive	JJ	positive	positive	posit	N	O
in	IN	in	in	in	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
screening	NN	screening	screening	screen	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
treated	VBN	treated	treated	treat	N	O
according	VBG	according	according	accord	N	O
to	TO	to	to	to	N	O
standard	VB	standard	standard	standard	N	O
medical	JJ	medical	medical	medic	N	O
practice	NN	practice	practice	practic	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
therapy	VB	therapy	therapy	therapi	N	O
with	IN	with	with	with	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
.	.	.	.	.	N	O

All	DT	all	all	all	N	O
patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
instructed	VBN	instructed	instructed	instruct	N	O
to	TO	to	to	to	N	O
seek	VB	seek	seek	seek	N	O
medical	JJ	medical	medical	medic	N	O
advice	NN	advice	advice	advic	N	O
if	IN	if	if	if	N	O
signs	NNS	signs	sign	sign	N	O
,	,	,	,	,	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
high	JJ	high	high	high	N	O
risk	NN	risk	risk	risk	N	O
exposure	VBP	exposure	exposure	exposur	N	O
suggestive	NN	suggestive	suggestive	suggest	N	O
of	IN	of	of	of	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
persistent	JJ	persistent	persistent	persist	N	O
cough	NN	cough	cough	cough	Y	O
,	,	,	,	,	N	O
weight	JJ	weight	weight	weight	Y	O
loss	NN	loss	loss	loss	N	O
,	,	,	,	,	N	O
subfebrile	JJ	subfebrile	subfebrile	subfebril	N	O
temperature	NN	temperature	temperature	temperatur	N	O
)	)	)	)	)	N	O
appear	VBP	appear	appear	appear	N	O
during	IN	during	during	dure	N	O
or	CC	or	or	or	N	O
after	IN	after	after	after	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

Healthcare	NNP	healthcare	healthcare	healthcar	N	O
providers	NNS	providers	provider	provid	N	O
should	MD	should	should	should	N	O
follow	VB	follow	follow	follow	N	O
current	JJ	current	current	current	N	O
CDC	NNP	cdc	cdc	cdc	N	O
guidelines	NNS	guidelines	guideline	guidelin	N	O
both	DT	both	both	both	N	O
to	TO	to	to	to	N	O
evaluate	VB	evaluate	evaluate	evalu	N	O
for	IN	for	for	for	N	O
and	CC	and	and	and	N	O
to	TO	to	to	to	N	O
treat	VB	treat	treat	treat	N	O
possible	JJ	possible	possible	possibl	N	O
latent	JJ	latent	latent	latent	N	O
tuberculosis	NN	tuberculosis	tuberculosis	tuberculosi	Y	O
infections	NNS	infections	infection	infect	N	O
before	IN	before	before	befor	N	O
initiating	VBG	initiating	initiating	initi	N	O
therapy	NN	therapy	therapy	therapi	N	O
with	IN	with	with	with	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Immunosuppression	NN	immunosuppression	immunosuppression	immunosuppress	Y	O

The	DT	the	the	the	N	O
impact	NN	impact	impact	impact	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
interleukin	JJ	interleukin	interleukin	interleukin	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
IL	NNP	il	il	il	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
therapy	NN	therapy	therapy	therapi	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
development	NN	development	development	develop	N	O
of	IN	of	of	of	N	O
malignancies	NNS	malignancies	malignancy	malign	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
known	VBN	known	known	known	N	O
.	.	.	.	.	N	O

However	RB	however	however	howev	N	O
,	,	,	,	,	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
immunosuppressants	NNS	immunosuppressants	immunosuppressant	immunosuppress	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
,	,	,	,	,	N	O
may	MD	may	may	may	N	O
result	VB	result	result	result	N	O
in	IN	in	in	in	N	O
an	DT	an	an	an	N	O
increase	NN	increase	increase	increas	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
malignancies	NNS	malignancies	malignancy	malign	N	B-AdverseReaction
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O

Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

During	IN	during	during	dure	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
no	DT	no	no	no	N	B-Negation
anaphylactic	JJ	anaphylactic	anaphylactic	anaphylact	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
.	.	.	.	.	N	O

It	PRP	it	it	it	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
recognized	VBN	recognized	recognized	recogn	N	O
that	IN	that	that	that	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
underlying	JJ	underlying	underlying	underli	N	O
disease	NN	disease	disease	diseas	N	O
being	VBG	being	being	be	N	O
treated	VBN	treated	treated	treat	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
similar	JJ	similar	similar	similar	N	O
to	TO	to	to	to	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
.	.	.	.	.	N	O

ILARIS	NNP	ilaris	ilaris	ilari	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
administered	VBN	administered	administered	administ	N	O
to	TO	to	to	to	N	O
any	DT	any	any	ani	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
known	JJ	known	known	known	N	O
clinical	JJ	clinical	clinical	clinic	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
to	TO	to	to	to	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Contraindications	NNP	contraindications	contraindication	contraind	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.2	CD	6.2	6.2	6.2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
Immunizations	NNS	immunizations	immunization	immun	N	O

Live	JJ	live	live	live	N	O
vaccines	NNS	vaccines	vaccine	vaccin	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
given	VBN	given	given	given	N	O
concurrently	RB	concurrently	concurrently	concurr	N	O
with	IN	with	with	with	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Drug	NNP	drug	drug	drug	N	O
Interactions	NNP	interactions	interaction	interact	N	O
(	(	(	(	(	N	O
7.2	CD	7.2	7.2	7.2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Since	IN	since	since	sinc	N	O
no	DT	no	no	no	N	O
data	NNS	data	data	data	N	O
are	VBP	are	are	are	N	O
available	JJ	available	available	avail	N	O
on	IN	on	on	on	N	O
either	CC	either	either	either	N	O
the	DT	the	the	the	N	O
efficacy	NN	efficacy	efficacy	efficaci	N	O
or	CC	or	or	or	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
risks	NNS	risks	risk	risk	N	O
of	IN	of	of	of	N	O
secondary	JJ	secondary	secondary	secondari	N	O
transmission	NN	transmission	transmission	transmiss	N	O
of	IN	of	of	of	N	O
infection	NN	infection	infection	infect	Y	O
by	IN	by	by	by	N	O
live	JJ	live	live	live	N	O
vaccines	NNS	vaccines	vaccine	vaccin	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
,	,	,	,	,	N	O
live	JJ	live	live	live	N	O
vaccines	NNS	vaccines	vaccine	vaccin	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
given	VBN	given	given	given	N	O
concurrently	RB	concurrently	concurrently	concurr	N	O
with	IN	with	with	with	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
addition	NN	addition	addition	addit	N	O
,	,	,	,	,	N	O
because	IN	because	because	becaus	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
may	MD	may	may	may	N	B-Factor
interfere	VB	interfere	interfere	interfer	N	B-AdverseReaction
with	IN	with	with	with	N	I-AdverseReaction
normal	JJ	normal	normal	normal	N	I-AdverseReaction
immune	JJ	immune	immune	immun	N	I-AdverseReaction
response	NN	response	response	respons	N	I-AdverseReaction
to	TO	to	to	to	N	O
new	JJ	new	new	new	N	O
antigens	NNS	antigens	antigen	antigen	N	O
,	,	,	,	,	N	O
vaccinations	NNS	vaccinations	vaccination	vaccin	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
effective	JJ	effective	effective	effect	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
.	.	.	.	.	N	O

No	DT	no	no	no	N	O
data	NN	data	data	data	N	O
are	VBP	are	are	are	N	O
available	JJ	available	available	avail	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
effectiveness	NN	effectiveness	effectiveness	effect	N	O
of	IN	of	of	of	N	O
vaccinations	NNS	vaccinations	vaccination	vaccin	N	O
with	IN	with	with	with	N	O
inactivated	JJ	inactivated	inactivated	inactiv	N	O
(	(	(	(	(	N	O
killed	VBN	killed	killed	kill	N	O
)	)	)	)	)	N	O
antigens	NNS	antigens	antigen	antigen	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Drug	NNP	drug	drug	drug	N	O
Interactions	NNP	interactions	interaction	interact	N	O
(	(	(	(	(	N	O
7.2	CD	7.2	7.2	7.2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
IL	NNP	il	il	il	N	O
-	:	-	-	-	N	O
1	CD	1	1	1	N	O
blockade	NN	blockade	blockade	blockad	N	O
may	MD	may	may	may	N	O
interfere	VB	interfere	interfere	interfer	N	O
with	IN	with	with	with	N	O
immune	JJ	immune	immune	immun	N	O
response	NN	response	response	respons	N	O
to	TO	to	to	to	N	O
infections	NNS	infections	infection	infect	N	O
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
recommended	VBN	recommended	recommended	recommend	N	O
that	IN	that	that	that	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
therapy	NN	therapy	therapy	therapi	N	O
with	IN	with	with	with	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
,	,	,	,	,	N	O
adult	NN	adult	adult	adult	N	O
and	CC	and	and	and	N	O
pediatric	JJ	pediatric	pediatric	pediatr	N	O
patients	NNS	patients	patient	patient	N	O
receive	VBP	receive	receive	receiv	N	O
all	DT	all	all	all	N	O
recommended	VBD	recommended	recommended	recommend	N	O
vaccinations	NNS	vaccinations	vaccination	vaccin	N	O
,	,	,	,	,	N	O
as	IN	as	a	as	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
pneumococcal	JJ	pneumococcal	pneumococcal	pneumococc	N	O
vaccine	NN	vaccine	vaccine	vaccin	N	O
and	CC	and	and	and	N	O
inactivated	JJ	inactivated	inactivated	inactiv	N	O
influenza	NN	influenza	influenza	influenza	Y	O
vaccine	NN	vaccine	vaccine	vaccin	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
See	VB	see	see	see	N	O
current	JJ	current	current	current	N	O
recommended	VBN	recommended	recommended	recommend	N	O
immunization	NN	immunization	immunization	immun	Y	O
schedules	NNS	schedules	schedule	schedul	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
website	NN	website	website	websit	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
Centers	NNPS	centers	center	center	N	O
for	IN	for	for	for	N	O
Disease	NNP	disease	disease	diseas	N	O
Control	NNP	control	control	control	N	O
,	,	,	,	,	N	O
http	NN	http	http	http	N	O
:	:	:	:	:	N	O
www	NN	www	www	www	N	O
.	.	.	.	.	N	O
cdc	NN	cdc	cdc	cdc	N	O
.	.	.	.	.	N	O
gov	JJ	gov	gov	gov	N	O
vaccines	NNS	vaccines	vaccine	vaccin	N	O
schedules	NNS	schedules	schedule	schedul	N	O
index	NN	index	index	index	N	O
.	.	.	.	.	N	O
html	NN	html	html	html	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

5.5	CD	5.5	5.5	5.5	N	O
Macrophage	NNP	macrophage	macrophage	macrophag	N	O
Activation	NNP	activation	activation	activ	N	O
Syndrome	NNP	syndrome	syndrome	syndrom	N	O

Macrophage	NNP	macrophage	macrophage	macrophag	N	O
activation	NN	activation	activation	activ	N	O
syndrome	NN	syndrome	syndrome	syndrom	N	O
(	(	(	(	(	N	O
MAS	NNP	mas	ma	ma	N	O
)	)	)	)	)	N	O
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
known	NN	known	known	known	N	O
,	,	,	,	,	N	O
life	NN	life	life	life	N	O
-	:	-	-	-	N	O
threatening	VBG	threatening	threatening	threaten	N	O
disorder	NN	disorder	disorder	disord	N	O
that	WDT	that	that	that	N	O
may	MD	may	may	may	N	O
develop	VB	develop	develop	develop	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
rheumatic	JJ	rheumatic	rheumatic	rheumat	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
particular	JJ	particular	particular	particular	N	O
SJIA	NNP	sjia	sjia	sjia	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
aggressively	RB	aggressively	aggressively	aggress	N	O
treated	VBN	treated	treated	treat	N	O
.	.	.	.	.	N	O

Physicians	NNS	physicians	physician	physician	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
attentive	JJ	attentive	attentive	attent	N	O
to	TO	to	to	to	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
infection	NN	infection	infection	infect	Y	O
or	CC	or	or	or	N	O
worsening	NN	worsening	worsening	worsen	N	O
of	IN	of	of	of	N	O
SJIA	NNP	sjia	sjia	sjia	N	O
,	,	,	,	,	N	O
as	IN	as	a	as	N	O
these	DT	these	these	these	N	O
are	VBP	are	are	are	N	O
known	VBN	known	known	known	N	O
triggers	NNS	triggers	trigger	trigger	N	O
for	IN	for	for	for	N	O
MAS	NNP	mas	ma	ma	N	O
.	.	.	.	.	N	O

Eleven	JJ	eleven	eleven	eleven	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
MAS	NNP	mas	ma	ma	N	B-AdverseReaction
were	VBD	were	were	were	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
201	CD	201	201	201	N	O
SJIA	NNP	sjia	sjia	sjia	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBD	treated	treated	treat	N	O
with	IN	with	with	with	N	O
canakinumab	NN	canakinumab	canakinumab	canakinumab	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

Based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trial	NN	trial	trial	trial	N	O
experience	NN	experience	experience	experi	N	O
,	,	,	,	,	N	O
ILARIS	NNP	ilaris	ilaris	ilari	N	O
does	VBZ	does	doe	doe	N	O
not	RB	not	not	not	N	O
appear	VB	appear	appear	appear	N	O
to	TO	to	to	to	N	O
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
MAS	NNP	mas	ma	ma	N	B-AdverseReaction
in	IN	in	in	in	N	O
SJIA	NNP	sjia	sjia	sjia	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
but	CC	but	but	but	N	O
no	DT	no	no	no	N	B-Factor
definitive	JJ	definitive	definitive	definit	N	I-Factor
conclusion	NN	conclusion	conclusion	conclus	N	I-Factor
can	MD	can	can	can	N	O
be	VB	be	be	be	N	O
made	VBN	made	made	made	N	O
.	.	.	.	.	N	O

